SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BigKNY3 who wrote (12853)8/7/1998 1:19:00 AM
From: VLAD  Read Replies (1) of 23519
 
Big kahuna,

Yes and no.

Charlie O downgraded Vivus after the production shortfall and also reiterated a hold in the beginning of June with a Q3 estimate of -.43.

Now if you read his upgrade in the beginning of July, I see nothing that i can honestly say was "corrupt" or "manipulative". In fact all his points were valid and reasonable. IMO a price target of 20 within 12 months is by no means unrealistic. It gives Vivus a chance to prove itself via earnings over the next few quarters. The bottom line is that a return to profitability proves that MUSE is not a has been and will have its fair share of the global ED market.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News